A global private equity firm is looking to make direct equity investments into life science companies ranging from $5-25m, primarily in the USA and Europe, with the potential to invest in other areas if the right syndication opportunities are available.  The firm typically makes 10 new direct investments per year across a diverse range of sectors, including healthcare IT, therapeutics and medical devices.  The firm leads or co-leads financing rounds in about 60% of cases and takes a board seat in these instances, but on other occasions may syndicate with other investors and not take a board seat.

The firm prefers to invest in medical devices and therapeutics with the potential to become the standard of care in a large clinical area with unmet needs.  Focus indications include oncology, immunology, cardiology, diabetes, neurology, infectious diseases, respiratory disorders, pain management and psychiatry.  The firm prefers to invest in the later clinical stages (Phase II + III), but will consider opportunistic investments in earlier stage opportunities if the firm sees the potential for outsized risk-adjusted returns due to a market dislocation.

The firm also invests in healthcare IT companies that have a product already on the market and have attained revenue and customer adoption.  These investments are in a variety of market segments, including enterprise software, clinical management software, connected devices/equipment and direct-to-consumer products.

In the therapeutic and medical device sectors, the firm seeks to invest in companies with unique intellectual property and with strong investor syndicates who can fund late-stage clinical trials to completion.  In the healthcare IT sector, the firm prefers to invest in companies with at least $5m in revenue and strong, experienced management teams.  The firm performs thorough due diligence, looking at factors such as historical performance, size of market opportunity, revenue per customer and customer stickiness in addition to vetting the product itself and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a large pharmaceutical company is currently looking to make equity investments into early stage life science companies. The firm has the ability to allocate up to $10 million dollars per company, generally in milestone driven tranches. The firm is able to invest in companies from around the globe and is actively seeking new investment opportunities.

The firm is looking for early stage companies working with therapeutics and companion diagnostics. The firm is open to review both small molecules and biologics as well as companies working with single assets or platform technologies. The firm seeks to invest in indication areas including Immunology, Oncology, Immunoncology, MS, and Fertility. The firm generally looks for companies with assets that are pre-clinical or in Phase I of clinical trials.

The firm is looking for privately held companies with experienced management teams. The firm looks to take an active role following investing generally taking at least a board seat. The firm is willing to both lead rounds and co-invest as a member of a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the Western United State is currently investing out of its 2^nd fund. The firm makes primarily equity investments ranging from $50,000 to $5 million over the lifetime of the investment. The firm prefers to invest in companies located in United States although they are also open to review internationally based opportunities and are currently working with a few companies in Israel. The firm plans to make approximately 2 new investments over the next 6-9 months.

The firm is looking for seed and venture stage medical and diagnostic device companies. In these areas the firm is most interested in single use devices capable of delivering a therapy, and in indications such as cancer, cardiovascular and neurological diseases, orthopedic problems, respiratory conditions, and gastrointestinal disorders. While this is the firms primary focus, they remain open minded to other types of devices and indications as well.

The firm looks for professionalism in a firms management teams and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat into companies however they firm does look to add value by developing strategic corporate partnerships in Japan when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm funded entirely by its partners based in the United States is looking to make equity investment into early and mid-stage life science companies ranging from $500,000 to 2 million initially. The firm looks to get involved in Seed and Series A Rounds. The firm could make as many as 6 investments over the next 12 months and looks to invest in companies located throughout the United States, Europe and Israel.

The firm is currently interested in sectors of Therapeutics, and Diagnostics. The firm is open to review all types of molecules and platforms and is currently most interested in for companies working towards indications of Autism, CNS disorders, and Parkinson’s disease. The firm generally looks to get involved with companies that are at the pre-clinical stage of development.

The firm is looking for companies with driven, and talented management teams with strong IP for their products. The firm is looking to invest in privately held companies and looks to take an active role following investment generally as a member of the Board. The firm is very comfortable working with scientific founding teams.

A private investment group based in Canada is looking to make growth stage investments in medical device companies. The firm does not manage a committed fund of capital. The firm’s partners generally make up 20-25% of the capital and raises additional capital on a deal-by-deal basis from a small group of high net worth investors. The firm invests in companies that are based in North America. The firm is actively looking for new investment opportunities.

In the Life Sciences the firm is currently seeking to invest in medical devices with market approval. The firm is opportunistic in terms of the class and indications. Historically, the firm invested in an image guided medical laser technology although they are open to all recently approved devices.

ECP seeks to be an active investor and will require a board seat/observer rights. The firm only invests in commercial stage companies but the firm does not have revenue requirements.

The corporate venture capital arm of a large health care system in the United States is looking to invest in on early-stage companies across the healthcare sector. The firm typically allocates $500K to $1.5M initially and up to $3M over the life of an investment. The firm looks for companies that are based in the United States and is actively seeking new investment opportunities.

In the Life Sciences the firm is currently seeking to invest in medical devices and diagnostics devices. The firm looks for all classes of devices and is opportunistic in terms of indications. The firm will consider devices as early as in development stage and all the way to commercialization stage. Current investments include companies operating in wound care, neurovascular and surgical tools though they are open to all types of medical devices. The firm is most interest in devices that have a strong potential to lower healthcare cost, thus benefiting the firm’s parents company. The firm looks to invest in privately held companies with a strong and experienced management team.

A private investment firm located in the Northeastern United Sates is looking to make investments in the life sciences space, and does so on a case by case basis without a traditional fund structure. Since the members are investing their own capital, the investment size and capital structure are highly flexible and will depend on the financial needs of the company. However the minimum amount the fund is willing to invest is $2 million, and can go upwards of $40 million. The firm invests in private or public companies and prefers to be the lead investor, but is open to syndicate as well. The firm is willing to invest in opportunities from all across the Globe. The firm is looking to conduct as many investments as possible over the course of the next 12 months, and is open to qualified deal flow.

The firm is very opportunistic and will consider a broad range of life science opportunities. The firm will consider Biotech, Medical Technology, R&D services, however the firm prefers not to invest in Healthcare IT, Dermatology, or Wound Care. The firm focuses on companies with clinical assets with some efficacy data, through those who have products on the market are also considered. The firm has a strong interest in technologies that significantly improve the standard of care.

The firm evaluates the company’s management team on a case by case basis. The firm is open to working with both experienced teams, as well as new entrepreneurs, and only requires that the team be competent. The firm does not require a board seat.